BioNexus Gene Lab Corp. Completes Strategic RM 1 Million Investment in Ascension Innovation Sdn Bhd
BioNexus Gene Lab Corp. (NASDAQ: BGLC) has completed a strategic RM 1 million (approx. USD228k) investment in Ascension Innovation Sdn Bhd (AISB), a Malaysian healthcare technology firm. The investment, made through BGLC's subsidiary MRNA Scientific Sdn Bhd, gives BGLC a significant equity stake in AISB.
AISB specializes in innovative healthcare technologies, particularly its aiCMS platform, which integrates predictive analytics and AI tools for clinical management. This collaboration aims to combine BGLC's expertise in blood-based genomic screening with AISB's AI-driven platforms to enhance diagnostics and personalized healthcare solutions.
The investment aligns with BGLC's strategy to expand in the growing digital health and AI markets, potentially improving patient outcomes through more accurate diagnostics and tailored treatments.
BioNexus Gene Lab Corp. (NASDAQ: BGLC) ha completato un investimento strategico di RM 1 milione (circa USD228k) in Ascension Innovation Sdn Bhd (AISB), un'azienda malese di tecnologia sanitaria. L'investimento, effettuato tramite la sussidiaria di BGLC MRNA Scientific Sdn Bhd, conferisce a BGLC una partecipazione azionaria significativa in AISB.
AISB si specializza in tecnologie sanitarie innovative, in particolare nella sua piattaforma aiCMS, che integra analisi predittive e strumenti AI per la gestione clinica. Questa collaborazione mira a combinare l'expertise di BGLC nello screening genomico basato sul sangue con le piattaforme guidate da AI di AISB per migliorare le diagnosi e le soluzioni sanitarie personalizzate.
L'investimento è in linea con la strategia di BGLC di espandersi nei crescenti mercati della salute digitale e dell'AI, potenzialmente migliorando gli esiti per i pazienti attraverso diagnosi più accurate e trattamenti su misura.
BioNexus Gene Lab Corp. (NASDAQ: BGLC) ha completado una inversión estratégica de RM 1 millón (aproximadamente USD228k) en Ascension Innovation Sdn Bhd (AISB), una empresa malaya de tecnología en salud. La inversión, realizada a través de la subsidiaria de BGLC MRNA Scientific Sdn Bhd, le otorga a BGLC una participación significativa en AISB.
AISB se especializa en tecnologías de salud innovadoras, particularmente en su plataforma aiCMS, que integra análisis predictivos y herramientas de IA para la gestión clínica. Esta colaboración tiene como objetivo combinar la experiencia de BGLC en cribado genómico basado en sangre con las plataformas impulsadas por IA de AISB para mejorar los diagnósticos y las soluciones de salud personalizadas.
La inversión está alineada con la estrategia de BGLC de expandirse en los crecientes mercados de salud digital e IA, lo que puede mejorar los resultados de los pacientes a través de diagnósticos más precisos y tratamientos personalizados.
BioNexus Gene Lab Corp. (NASDAQ: BGLC)는 말레이시아의 의료 기술 회사인 Ascension Innovation Sdn Bhd (AISB)에 RM 1 백만 (약 USD228k)의 전략적 투자를 완료했습니다. 이 투자는 BGLC의 자회사 MRNA Scientific Sdn Bhd를 통해 이루어졌으며, BGLC는 AISB에 대한 상당한 지분을 보유하게 되었습니다.
AISB는 혁신적인 의료 기술, 특히 임상 관리를 위한 예측 분석 및 AI 도구를 통합하는 aiCMS 플랫폼에 특화되어 있습니다. 이 협업은 BGLC가 혈액 기반 유전체 검사에서의 전문성과 AISB의 AI 기반 플랫폼을 결합하여 진단 및 개인화된 의료 솔루션을 향상시키는 것을 목표로 합니다.
이 투자는 환자 결과를 보다 정확한 진단과 맞춤형 치료를 통해 개선할 수 있는 디지털 건강 및 AI 시장에서 BGLC의 확장을 위한 전략과 일치합니다.
BioNexus Gene Lab Corp. (NASDAQ: BGLC) a complété un investissement stratégique de RM 1 million (environ USD228k) dans Ascension Innovation Sdn Bhd (AISB), une entreprise malaisienne de technologie de la santé. Cet investissement, réalisé par l'intermédiaire de la filiale de BGLC, MRNA Scientific Sdn Bhd, donne à BGLC une participation significative dans AISB.
AISB se spécialise dans les technologies de santé innovantes, en particulier avec sa plateforme aiCMS, qui intègre des analyses prédictives et des outils d'IA pour la gestion clinique. Cette collaboration vise à combiner l'expertise de BGLC en dépistage génomique basé sur le sang avec les plateformes basées sur l'IA d'AISB afin d'améliorer les diagnostics et les solutions de santé personnalisées.
L'investissement est en accord avec la stratégie de BGLC d'expansion sur les marchés en pleine croissance de la santé numérique et de l'IA, ce qui pourrait améliorer les résultats des patients grâce à des diagnostics plus précis et des traitements sur mesure.
BioNexus Gene Lab Corp. (NASDAQ: BGLC) hat eine strategische Investition von RM 1 Million (ca. USD228k) in Ascension Innovation Sdn Bhd (AISB), ein malaysisches Unternehmen für Medizintechnologie, abgeschlossen. Die Investition, die über die Tochtergesellschaft von BGLC, MRNA Scientific Sdn Bhd, getätigt wurde, verschafft BGLC einen bedeutenden Anteil an AISB.
AISB ist auf innovative Medizintechnologien spezialisiert, insbesondere auf die aiCMS-Plattform, die prädiktive Analytik und KI-Tools für das klinische Management integriert. Diese Zusammenarbeit zielt darauf ab, die Expertise von BGLC im Bereich des blutbasierten genomischen Screenings mit den KI-gesteuerten Plattformen von AISB zu kombinieren, um Diagnosen und personalisierte Gesundheitslösungen zu verbessern.
Die Investition steht im Einklang mit der Strategie von BGLC, sich auf den wachsenden Märkten für digitale Gesundheit und KI zu expandieren, was potenziell die Patientenergebnisse durch genauere Diagnosen und maßgeschneiderte Behandlungen verbessern kann.
- Strategic investment of RM 1 million (USD228k) in Ascension Innovation Sdn Bhd
- Acquisition of significant equity stake in AISB
- Potential synergies between BGLC's genomic screening and AISB's AI technology
- Expansion into rapidly growing digital health sector
- Opportunity to enhance diagnostic accuracy and personalized healthcare solutions
- None.
Insights
This
The collaboration between BGLC and AISB represents a significant technological leap in healthcare. AISB's aiCMS platform, which integrates predictive analytics and AI tools, could dramatically enhance the precision and efficiency of BGLC's genomic screening services. This synergy has the potential to create a powerful offering in personalized medicine. The integration of AI with genomic data could lead to more accurate diagnostics and tailored treatment plans, addressing a critical need in healthcare. However, the success of this venture will depend on the seamless integration of these technologies and their adoption by healthcare providers. Investors should monitor the progress of this integration and any resulting improvements in BGLC's service offerings or market penetration.
BGLC's investment in AISB aligns with the rapidly growing digital health and AI markets. The global digital health market is projected to reach
KUALA LUMPUR, Malaysia, Aug. 27, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ: BGLC), an emerging leader in genomic diagnostics and health technology, today announced the successful closing of its RM 1 million (Approx. USD228k) investment in Ascension Innovation Sdn Bhd (AISB), a pioneering Malaysian healthcare technology firm. This strategic investment, executed through BGLC’s wholly-owned subsidiary, MRNA Scientific Sdn Bhd, solidifies BGLC’s commitment to advancing AI-driven healthcare solutions.
AISB specializes in innovative healthcare technologies, particularly through its flagship platform, aiCMS, which integrates advanced predictive analytics and AI tools to enhance clinical management and patient care. The investment provides BGLC with a significant equity stake in AISB, enabling deeper collaboration between the two companies.
Sam Tan, Chief Executive Officer of BioNexus Gene Lab Corp., stated, “Our investment in Ascension Innovation represents a critical step in expanding our presence in the rapidly growing digital health sector. By leveraging AISB’s cutting-edge AI technology, we aim to enhance our genomic screening services and deliver more personalized healthcare solutions to a broader audience.”
This collaboration is expected to create synergies between BGLC’s expertise in blood-based genomic screening and AISB’s innovative AI-driven platforms. The integration of these technologies will enable healthcare providers to offer more accurate diagnostics and tailored treatments, ultimately improving patient outcomes.
Andrew Teng, Chief Executive Officer of Ascension Innovation Sdn Bhd, added, “We are excited to partner with BioNexus Gene Lab Corp. and look forward to transforming the healthcare landscape through the integration of advanced AI and genomic technologies.”
The investment is part of BGLC’s broader strategy to capitalize on the expanding digital health and AI markets, which are projected to experience significant growth over the coming years. The Management of BGLC continues to monitor and look for opportunities to grow the value of the investment.
About BioNexus Gene Lab Corp.
BioNexus Gene Lab Corp. (NASDAQ: BGLC) is a global leader in RNA-based genomic diagnostics, committed to advancing personalized medicine and improving global health outcomes.
For more information, visit www.bionexusgenelab.com.
About Ascension Innovation Sdn Bhd
Ascension Innovation Sdn Bhd is a leading healthcare technology company focused on innovative AI-driven solutions. Visit www.aisb.io for more details.
Investor Relations
BioNexus Gene Lab Corporation
Email: ir@bionexusgenelab.com
FAQ
What is the value of BioNexus Gene Lab Corp's investment in Ascension Innovation Sdn Bhd?
How does the investment in AISB align with BGLC's business strategy?
What is the main technology offered by Ascension Innovation Sdn Bhd (AISB)?
How might BGLC's investment in AISB impact patient care?
